Taofeek K. Owonikoko, MD, PhD - Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Go online to PeerView.com/XXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recently validated and emerging therapies are providing new hope for patients with small cell lung cancer (SCLC). In patients with extensive-stage or metastatic disease, regulatory approvals of chemo-immunotherapy combinations, the transcription inhibitor lurbinectedin, and the myeloprotective agent trilaciclib have led to new guideline-recommended standards of care. Further progress is expected as ongoing clinical trials are evaluating existing therapies in different settings, including in earlier stages of disease and in various combinations, as well as promising novel therapies and rational combinations employing different agent classes and mechanisms of action. Bringing these treatment advances to the clinic comes with unique challenges, from sifting through data to ensure that patients benefit from these treatment advances and determining which patients are eligible for clinical trial enrollment to collaborating with the multidisciplinary team to manage unique adverse events associated with novel treatments and counseling patients. In this PeerView Candid Conversations & Clinical Consults program, leading experts will provide oncology specialists and multidisciplinary professionals who treat patients with lung cancer with the information they need to navigate the evidence on current and emerging therapies for SCLC. With illustrative cases serving as the cornerstone of the discussion, this activity will go beyond the basics of treatment and provide an intimate look at how top lung cancer specialists bring therapeutic advances into their own practices and what they think the future will bring. Learn about new data, guideline recommendations, and strategies to improve multidisciplinary collaboration and care; increase shared decision-making; and promote health equity in SCLC clinical care and research. Upon completion of this activity, participants should be better able to: Cite the latest evidence on available and emerging therapeutics in SCLC, including immunotherapy, transcription inhibitors, myeloprotective therapies, and other strategies, as well as emerging prospects in biomarker testing and subtyping that may help inform selection of patients for different therapies; Incorporate new and emerging therapies into individualized treatment plans for eligible patients with SCLC in clinical practice or clinical trials based on the latest evidence, guidelines, and patient needs, values, and preferences; Utilize best practices for diagnosing and managing treatment-related toxicity in patients with SCLC Implement multidisciplinary strategies and shared decision-making to ensure early diagnosis, individualized treatment, optimal management, and equitable care of patients with SCLC